ORIENTBIO, Inc.

As of June 30, 2026, ORIENTBIO, Inc. carries a market capitalization of 104.95B, placing it among publicly traded companies globally. Its enterprise value stands at 68.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ORIENTBIO, Inc. has 59.29M shares outstanding.

As of June 30, 2026, ORIENTBIO, Inc. trades at a trailing price-to-earnings ratio of 39.72. The price-to-sales ratio is 3.20, and the price-to-book ratio stands at 1.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.37 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. ORIENTBIO, Inc. trades at an EV/FCF ratio of 11.35, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 68.06B versus a market cap of 104.95B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ORIENTBIO, Inc. maintains a current ratio of 14.09, meaning it holds 14.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.65, indicating elevated leverage, while an interest coverage ratio of -1.29 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ORIENTBIO, Inc. posted a return on equity (ROE) of 3.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -3.49, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 2.78, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.31, useful for judging operating efficiency across full business cycles. The company generates approximately 233.05M in revenue per employee across its workforce of 123.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.77 indicates how many times ORIENTBIO, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, ORIENTBIO, Inc.'s stock has declined approximately 41.38% over the past 52 weeks. The 50-day moving average sits at 1,782.10, while the 200-day moving average is 2,088.80.

Over the twelve months ended June 30, 2026, ORIENTBIO, Inc. generated 28.66B in revenue and converted that into 2.31B in net income, yielding earnings per share of 44.57. EBITDA reached -128.93M, while operating income came in at 2.85B.

As of June 30, 2026, ORIENTBIO, Inc. holds 38.08B in cash and equivalents against 1.19B in total debt, resulting in a net debt position of -10.95B. Total book value stands at 72.27B, with working capital of 46.63B providing operational flexibility.

ORIENTBIO, Inc. produced 7.09B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.20B in capital expenditures, free cash flow totaled 5.90B - equivalent to 113.67 per share.

Over the twelve months ended June 30, 2026, ORIENTBIO, Inc. posted a gross margin of 22.59, reflecting its pricing power and cost economics. The operating margin of 9.93 and net profit margin of 8.07 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.63, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ORIENTBIO, Inc. shareholders.

ORIENTBIO, Inc.'s most recent stock split took place on September 22, 2026 with a 2:1 split ratio.

As of June 30, 2026, ORIENTBIO, Inc. has an Altman Z-Score of 6.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.